To receive POXEL information in real time, send a request to [email protected]
LYON, France, November 20, 2020 – POXEL SA (Euronext: POXEL – FR0012432516), a biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today hui that following a strategic review of its activities, Metavant decided not to pursue the development of Imeglimin. This decision is not related to the efficacy, safety, or any other data generated on Imeglimin during the partnership.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.